QBiotics is solving major health issues for humans and companion animals. We discover, develop and commercialise novel pharmaceuticals based on plant-derived cell-signalling molecules sourced from the Australian tropical rainforest, and underpinned by our discovery platform EcoLogic™. We simultaneously develop our products for the human and veterinary markets, delivering early to market veterinary products as well as real world animal data that informs and de-risks early stages of our human programmes. We currently have two leading programmes. The first is an oncology drug, tigilanol tiglate, with activity against a range of solid tumours. Tigilanol tiglate is now registered as a veterinary pharmaceutical, brand name STELFONTA®, and is marketed in the US, EU, UK and Australia. The drug is also currently in human Phase II clinical development. Our second programme is a pharmaceutical, EBC-1013, that addresses all the requirements for healing chronic and acute wounds. We have a very skilled and enthusiastic team of 61 employees.